This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Save to my personal folders Download to citation manager Rights & Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Sloan, J. A. Articles by Windschitl, H. Search for Related Content PubMed PubMed Citation Articles by Sloan, J. A. Articles by Windschitl, H. Social Bookmarking                            What's this?

Methodologic Lessons Learned From Hot Flash Studies

From the Mayo Clinic, Rochester, and CentraCare Clinic, St Cloud, MN; and Ann Arbor Regional Community Clinical Oncology Program, Ann Arbor, MI.

Address reprint requests to Charles L. Loprinzi, MD, Division of Medical Oncology, Mayo Clinic, 200 1st St SW, Rochester, MN 55905; email: cloprinzi{at}mayo.edu

PURPOSE: In the course of conducting a series of prospective clinical trials devoted to defining new treatment opportunities for hot flashes in cancer survivors, considerable experience has been acquired with related methodologic issues. This article has been written in response to many queries regarding this methodology.

PATIENTS AND METHODS: A series of seven different clinical trials that involved 968 patients was used for this work. Reliable and valid definitions of hot flash intensity were developed from patient-reported descriptions. Concomitant validity and reliability assessment of patient-completed diaries was undertaken to compare hot flash data with toxicity and quality-of-life (QOL) end points and to examine consistency across patient groups using variability analysis and correlation procedures. Parametric data from this meta-analysis was used to examine relative power considerations for the design of phase II and phase III clinical trials.

RESULTS: Daily diaries used in these studies exhibited consistency and reliability and had few missing data. Hot flash frequency and hot flash score (frequency multiplied by average severity) variables produced almost identical end point results. For phase III placebo-controlled studies, 50 patients per treatment arm seem appropriate to provide sufficient power specifications to detect a clinically meaningful change in hot flash activity. For phase II trials, 25 patients per trial seem to provide reasonable estimates of eventual hot flash efficacy to screen potential agents for more definitive testing.

CONCLUSION: Given the data gained from these experiences, we can plan and carry out more efficient trials to identify efficacious agents for the reduction of hot flash activity.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				J. Savard, J. Villa, H. Ivers, S. Simard, and C. M. Morin Prevalence, Natural Course, and Risk Factors of Insomnia Comorbid With Cancer Over a 2-Month Period J. Clin. Oncol., November 1, 2009; 27(31): 5233 - 5239. [Abstract] [Full Text] [PDF]

				H. de Boer, P. van Gastel, and A. van Sorge Luteinizing Hormone-Releasing Hormone and Postmenopausal Flushing N. Engl. J. Med., September 17, 2009; 361(12): 1218 - 1219. [Full Text] [PDF]

				C. L. Loprinzi, J. Sloan, V. Stearns, R. Slack, M. Iyengar, B. Diekmann, G. Kimmick, J. Lovato, P. Gordon, K. Pandya, et al. Newer Antidepressants and Gabapentin for Hot Flashes: An Individual Patient Pooled Analysis J. Clin. Oncol., June 10, 2009; 27(17): 2831 - 2837. [Abstract] [Full Text] [PDF]

				T. J. Smith Magnesium Supplements for Menopausal Hot Flashes J. Clin. Oncol., March 1, 2009; 27(7): 1151 - 1152. [Full Text] [PDF]

				C. L. Loprinzi, A. C. Dueck, B. S. Khoyratty, D. L. Barton, S. Jafar, K. M. Rowland Jr, P. J. Atherton, G. W. Marsa, W. H. Knutson, J. D. Bearden III, et al. A phase III randomized, double-blind, placebo-controlled trial of gabapentin in the management of hot flashes in men (N00CB) Ann. Onc., March 1, 2009; 20(3): 542 - 549. [Abstract] [Full Text] [PDF]

				J. Zhou, F. Qu, X. Sang, X. Wang, and R. Nan Acupuncture and Auricular Acupressure in Relieving Menopausal Hot Flashes of Bilaterally Ovariectomized Chinese Women: A Randomized Controlled Trial Evid. Based Complement. Altern. Med., February 2, 2009; (2009) nep001v1. [Abstract] [Full Text] [PDF]

				Y. Jin, D. F. Hayes, L. Li, J. D. Robarge, T. C. Skaar, S. Philips, A. Nguyen, A. Schott, J. Hayden, S. Lemler, et al. Estrogen Receptor Genotypes Influence Hot Flash Prevalence and Composite Score Before and After Tamoxifen Therapy J. Clin. Oncol., December 20, 2008; 26(36): 5849 - 5854. [Abstract] [Full Text] [PDF]

				S. L. Crawford, N. E. Avis, E. Gold, J. Johnston, J. Kelsey, N. Santoro, M. Sowers, and B. Sternfeld Sensitivity and Specificity of Recalled Vasomotor Symptoms in a Multiethnic Cohort Am. J. Epidemiol., December 15, 2008; 168(12): 1452 - 1459. [Abstract] [Full Text] [PDF]

				G. Elkins, J. Marcus, V. Stearns, M. Perfect, M. H. Rajab, C. Ruud, L. Palamara, and T. Keith Randomized Trial of a Hypnosis Intervention for Treatment of Hot Flashes Among Breast Cancer Survivors J. Clin. Oncol., November 1, 2008; 26(31): 5022 - 5026. [Abstract] [Full Text] [PDF]

				N. E. Avis Breast Cancer Survivors and Hot Flashes: The Search for Nonhormonal Treatments J. Clin. Oncol., November 1, 2008; 26(31): 5008 - 5010. [Full Text] [PDF]

				J. W. Goodwin, S. J. Green, C. M. Moinpour, J. D. Bearden III, J. K. Giguere, C. S. Jiang, S. M. Lippman, S. Martino, and K. S. Albain Phase III Randomized Placebo-Controlled Trial of Two Doses of Megestrol Acetate as Treatment for Menopausal Symptoms in Women With Breast Cancer: Southwest Oncology Group Study 9626 J. Clin. Oncol., April 1, 2008; 26(10): 1650 - 1656. [Abstract] [Full Text] [PDF]

				J. S. Carpenter and D. Flockhart Flash Points J. Clin. Oncol., December 10, 2007; 25(35): 5546 - 5547. [Full Text] [PDF]

				G. Deng, A. J. Vickers, K. S. Yeung, G. M. D'Andrea, H. Xiao, A. S. Heerdt, S. Sugarman, T. Troso-Sandoval, A. D. Seidman, C. A. Hudis, et al. Randomized, Controlled Trial of Acupuncture for the Treatment of Hot Flashes in Breast Cancer Patients J. Clin. Oncol., December 10, 2007; 25(35): 5584 - 5590. [Abstract] [Full Text] [PDF]

				J. A. Sloan, L. Berk, J. Roscoe, M. J. Fisch, E. G. Shaw, G. Wyatt, G. R. Morrow, and A. C. Dueck Integrating Patient-Reported Outcomes Into Cancer Symptom Management Clinical Trials Supported by the National Cancer Institute Sponsored Clinical Trials Networks J. Clin. Oncol., November 10, 2007; 25(32): 5070 - 5077. [Abstract] [Full Text] [PDF]

				S Loibl, K Schwedler, G von Minckwitz, R Strohmeier, K. Mehta, and M Kaufmann Venlafaxine is superior to clonidine as treatment of hot flashes in breast cancer patients--a double-blind, randomized study Ann. Onc., April 1, 2007; 18(4): 689 - 693. [Abstract] [Full Text] [PDF]

				C. L. Loprinzi, J. W. Kugler, D. L. Barton, A. C. Dueck, L. K. Tschetter, R. A. Nelimark, E. P. Balcueva, K. N. Burger, P. J. Novotny, M. D. Carlson, et al. Phase III Trial of Gabapentin Alone or in Conjunction With an Antidepressant in the Management of Hot Flashes in Women Who Have Inadequate Control With an Antidepressant Alone: NCCTG N03C5 J. Clin. Oncol., January 20, 2007; 25(3): 308 - 312. [Abstract] [Full Text] [PDF]

				J. S. Carpenter, A. M. Storniolo, S. Johns, P. O. Monahan, F. Azzouz, J. L. Elam, C. S. Johnson, and R. C. Shelton Randomized, Double-Blind, Placebo-Controlled Crossover Trials of Venlafaxine for Hot Flashes After Breast Cancer Oncologist, January 1, 2007; 12(1): 124 - 135. [Abstract] [Full Text] [PDF]

				M. M. Ohayon Severe hot flashes are associated with chronic insomnia. Arch Intern Med, June 26, 2006; 166(12): 1262 - 1268. [Abstract] [Full Text] [PDF]

				B. A. Pockaj, J. G. Gallagher, C. L. Loprinzi, P. J. Stella, D. L. Barton, J. A. Sloan, B. I. Lavasseur, R. M. Rao, T. R. Fitch, K. M. Rowland, et al. Phase III Double-Blind, Randomized, Placebo-Controlled Crossover Trial of Black Cohosh in the Management of Hot Flashes: NCCTG Trial N01CC1 J. Clin. Oncol., June 20, 2006; 24(18): 2836 - 2841. [Abstract] [Full Text] [PDF]

				A. H. Boekhout, J. H. Beijnen, and J. H.M. Schellens Symptoms and treatment in cancer therapy-induced early menopause. Oncologist, June 1, 2006; 11(6): 641 - 654. [Abstract] [Full Text] [PDF]

				H. D. Nelson, K. K. Vesco, E. Haney, R. Fu, A. Nedrow, J. Miller, C. Nicolaidis, M. Walker, and L. Humphrey Nonhormonal therapies for menopausal hot flashes: systematic review and meta-analysis. JAMA, May 3, 2006; 295(17): 2057 - 2071. [Abstract] [Full Text] [PDF]

				C. L. Loprinzi, R. Levitt, D. Barton, J. A. Sloan, S. R. Dakhil, D. A. Nikcevich, J. D. Bearden III, J. A. Mailliard, L. K. Tschetter, T. R. Fitch, et al. Phase III Comparison of Depomedroxyprogesterone Acetate to Venlafaxine for Managing Hot Flashes: North Central Cancer Treatment Group Trial N99C7 J. Clin. Oncol., March 20, 2006; 24(9): 1409 - 1414. [Abstract] [Full Text] [PDF]

				W. He and W. Deng Identifying methodologies in the assessment of treatment effects on the repeated occurrences of hot flashes in postmenopausal women Clinical Trials, December 1, 2005; 2(6): 497 - 508. [Abstract] [PDF]

				V. Stearns, R. Slack, N. Greep, R. Henry-Tilman, M. Osborne, C. Bunnell, L. Ullmer, A. Gallagher, J. Cullen, E. Gehan, et al. Paroxetine Is an Effective Treatment for Hot Flashes: Results From a Prospective Randomized Clinical Trial J. Clin. Oncol., October 1, 2005; 23(28): 6919 - 6930. [Abstract] [Full Text] [PDF]

				C. L. Loprinzi, D. L. Barton, L. A. Carpenter, J. A. Sloan, P. J. Novotny, M. T. Gettman, and B. J. Christensen Pilot Evaluation of Paroxetine for Treating Hot Flashes in Men Mayo Clin. Proc., October 1, 2004; 79(10): 1247 - 1251. [Abstract] [PDF]

				S. E Fugate and C. O Church Nonestrogen Treatment Modalities for Vasomotor Symptoms Associated with Menopause Ann. Pharmacother., September 1, 2004; 38(9): 1482 - 1499. [Abstract] [Full Text] [PDF]

				C. A. Thompson, T. D. Shanafelt, and C. L. Loprinzi Andropause: Symptom Management for Prostate Cancer Patients Treated With Hormonal Ablation Oncologist, October 1, 2003; 8(5): 474 - 487. [Abstract] [Full Text] [PDF]

				J. A. Tice, B. Ettinger, K. Ensrud, R. Wallace, T. Blackwell, and S. R. Cummings Phytoestrogen Supplements for the Treatment of Hot Flashes: The Isoflavone Clover Extract (ICE) Study: A Randomized Controlled Trial JAMA, July 9, 2003; 290(2): 207 - 214. [Abstract] [Full Text] [PDF]

				V. Stearns, K. L. Beebe, M. Iyengar, and E. Dube Paroxetine Controlled Release in the Treatment of Menopausal Hot Flashes: A Randomized Controlled Trial JAMA, June 4, 2003; 289(21): 2827 - 2834. [Abstract] [Full Text] [PDF]

				L. A. Fitzpatrick and R. J. Santen Hot Flashes: The Old and the New, What Is Really True? Mayo Clin. Proc., November 1, 2002; 77(11): 1155 - 1158. [PDF]

				C. L. Loprinzi, D. L. Barton, J. A. Sloan, K. M. Zahasky, D. A. R. Smith, S. Pruthi, P. J. Novotny, E. A. Perez, and B. J. Christensen Pilot Evaluation of Gabapentin for Treating Hot Flashes Mayo Clin. Proc., November 1, 2002; 77(11): 1159 - 1163. [Abstract] [PDF]

				V. Stearns and D. F. Hayes Cooling Off Hot Flashes J. Clin. Oncol., March 15, 2002; 20(6): 1436 - 1438. [Full Text] [PDF]

				C. L. Loprinzi, J. A. Sloan, E. A. Perez, S. K. Quella, P. J. Stella, J. A. Mailliard, M. Y. Halyard, S. Pruthi, P. J. Novotny, and T. A. Rummans Phase III Evaluation of Fluoxetine for Treatment of Hot Flashes J. Clin. Oncol., March 15, 2002; 20(6): 1578 - 1583. [Abstract] [Full Text] [PDF]

				J. Sloan Asking the Obvious Questions Regarding Patient Burden J. Clin. Oncol., January 1, 2002; 20(1): 4 - 6. [Full Text] [PDF]